Ori Biotech, a leader in cell and gene therapy (CGT) manufacturing technology, and ImmuXell Biotech, a Shanghai-based clinical-stage cell therapy company, announced their strategic partnership which...

SK bioscience announced that it has signed an agreement with Colombia's state-owned pharmaceutical company VECOL for vaccine technology transfer and local manufacturing cooperation as part of Colombia's...

LIB Therapeutics Inc. (LIB), a privately-held, biopharmaceutical company with a recently approved novel, monthly, small-dose, third-generation PCSK9 inhibitor, LEROCHOL® (lerodalcibep-liga),...

H. Lundbeck A/S (Lundbeck) announced that the Ministry of Food and Drug Safety (MFDS) of South Korea has granted marketing authorization for eptinezumab for use in adults with...

Hologic, Inc. and its subsidiary, Biotheranostics, Inc., announced new data demonstrating how the Breast Cancer Index® (BCI™) Test results influence extended endocrine therapy decisions for patients with...

Aspera Biomedicines Inc., a biotechnology company developing first-in-class therapies targeting cancer stem cells, announced that its second ADAR1p150 protein crystallization experiment has...

Galvanize Therapeutics, Inc., a commercial-stage medical technology company pioneering pulsed electric field (PEF) therapies for oncology and chronic lung disease, today announced that it received...

BD (Becton, Dickinson and Company) a leading global medical technology company, today announced that Peter Menziuso has been named executive vice president and president, BD Interventional,...

Ferring Pharmaceuticals announced a new real-world case series demonstrating that re-induction with ADSTILADRIN® (nadofaragene firadenovec-vncg) resulted in complete responses (CR) in approximately...

The concept of biohacking often brings to mind performance tracking and high-tech optimization – but at its core, it's a mindset grounded in understanding how the body functions and supporting it to...

AstraZeneca and Daiichi Sankyo’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been approved by the US Food and Drug Administration (FDA) for both the neoadjuvant and adjuvant treatment of patients...

High-level results from a planned interim analysis of the VOLGA Phase III trial showed perioperative treatment with IMFINZI® (durvalumab) in combination with neoadjuvant enfortumab vedotin (EV)...